| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| NodThera Adds $55M to Advance Drugs to Better Regulate Inflammation | Sarah de Crescenzo | 06/03/20 | Boston |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech | Editors | 05/27/20 | Boston |
| Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq | Frank Vinluan | 05/22/20 | National |
| Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More | Frank Vinluan | 05/22/20 | National |
| ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon | Frank Vinluan | 05/15/20 | New York |
| Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study | Sarah de Crescenzo | 05/11/20 | National |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Encouraging Signals for New Cancer Cell Therapy Strategies | Mandy Jackson | 05/06/20 | National |
| Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More | Sarah de Crescenzo | 05/01/20 | National |
| ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans | Frank Vinluan | 04/27/20 | New York |
| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) | Frank Vinluan | 04/22/20 | National |
| Cara Therapeutics Itching Drug Scratches Off Goals of Phase 3 Test | Frank Vinluan | 04/21/20 | New York |
| New COVID-19 Special Reports Explore Clinical Research During the Pandemic | Editors | 04/21/20 | Boston |
| Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More | Sarah de Crescenzo | 04/17/20 | National |
| GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year | Frank Vinluan | 04/14/20 | National |
| Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran | Frank Vinluan | 04/13/20 | Boston |
| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics | Frank Vinluan | 04/08/20 | Boston |
| Creating Consistent Value in Biotech Without Diluting Stakeholders | Alexis Peyroles | 04/07/20 | National |
| GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months | Frank Vinluan | 04/06/20 | San Francisco |
| Dynacure Adds $55M As RNA-Targeted Muscle Disorder Drug Enters Clinic | Sarah de Crescenzo | 04/03/20 | Boston |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| Tapping Into the Innovation Grid: J&J, Data, and a Shifting Healthcare Focus | Dan Stanton | 03/31/20 | Europe |
| Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance | Frank Vinluan | 03/27/20 | Europe |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics | Frank Vinluan | 03/25/20 | Europe |
| FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes | Frank Vinluan | 03/23/20 | Europe |
